Journal Article

DKFZ-2024-02765

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions.

Lamoureux, A.-A. ; Fisher, M. J. ; Lemelle, L. ; Pfaff, E.DKFZ* ; Amir-Yazdani, P. ; Kramm, C. ; De Wilde, B. ; Kazanowska, B. ; Hutter, C. ; Pfister, S.DKFZ* ; Sturm, D.DKFZ* ; Jones, D.DKFZ* ; Orbach, D. ; Pierron, G. ; Raskin, S. ; Drilon, A. ; Diamond, E. L. ; Harada, G. ; Zapotocky, M. ; Zamecnik, J. ; Krskova, L. ; Ellezam, B. ; Weil, A. G. ; Venne, D. ; Barritault, M. ; Leblond, P. ; Coltin, H. ; Hammad, R. ; Tabori, U. ; Hawkins, C. ; Hansford, J. R. ; Meyran, D. ; Erker, C. ; McFadden, K. ; Sato, M. ; Gottardo, N. G. ; Dholaria, H. ; Nørøxe, D. S. ; Goto, H. ; Ziegler, D. S. ; Lin, F. Y. ; Parsons, D. W. ; Lindsay, H. ; Wong, T.-T. ; Liu, Y.-L. ; Wu, K.-S. ; Franson, A. T. ; Hwang, E. ; Aguilar-Bonilla, A. ; Cheng, S. ; Cacciotti, C. ; Massimino, M. ; Schiavello, E. ; Wood, P. ; Hoffman, L. M. ; Cappellano, A. ; Lassaletta, A. ; Van Damme, A. ; Llort, A. ; Gerber, N. U. ; Spalato Ceruso, M. ; Bendel, A. E. ; Skrypek, M. ; Hamideh, D. ; Mushtaq, N. ; Walter, A. ; Jabado, N. ; Alsahlawi, A. ; Farmer, J.-P. ; Coleman, C. ; Mueller, S. ; Mazewski, C. ; Aguilera, D. ; Robison, N. J. ; O'Halloran, K. ; Abbou, S. ; Berlanga, P. ; Geoerger, B. ; Øra, I. ; Moertel, C. L. ; Razis, E. D. ; Vernadou, A. ; Ducray, F. ; Bronnimann, C. ; Seizeur, R. ; Clarke, M. ; Resnick, A. C. ; Alves, M. ; Jones, C. ; Doz, F. ; Laetsch, T. W. ; Perreault, S.

2025
AACR Philadelphia, Pa. [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1158/1078-0432.CCR-24-0581

Abstract: TRK fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients.We conducted an international retrospective cohort study of patients with TRK fusion-driven CNS tumors.119 patients were identified. The median age at time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG) (57.1%) followed by low-grade glioma (LGG) (27.7%). Pediatric patients had a better prognosis with a median overall survival of 185.5 months compared to 24.8 months in adults (p<.0001). Patients with LGG also had a better outcome when compared to HGG (p=0.0012). The objective response was 68.8% with larotrectinib compared to 38.1% for non-targeted treatment.Children with LGG glioma had a favorable outcome compared to adult and HGG. TRK inhibitors appear to improve tumor control.

Note: 2025 Feb 3;31(3):561-572

---

Contributing Institute(s):

1. Pädiatrische Gliomforschung (B360)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2024

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---